Hydroxocobalamin administration for treatment of vasoplegic syndrome associated with cardiopulmonary bypass causes red plasma

Saifee, Nabiha Huq; Sedgwick, Serena; Wu, Yanyun

doi:10.1111/trf.15615

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hydroxocobalamin, also known as vitamin B12, is a nitric oxide scavenger that has an emerging role as an adjunct therapy for VS not responsive to vasopressors. Hydroxocobalamin is known to cause red or purple discoloration of plasma and urine, which may result in interference with clinical laboratory assays that rely on colorimetric methodologies 3‐5 . Intravascular hemolysis was excluded by a stable hemoglobin (9.0 g/dL pre‐TPE, 8.9 g/dL post‐TPE).…”

Section: Figurementioning

confidence: 99%

Hydroxocobalamin mimicking intravascular hemolysis in therapeutic plasma exchange

Peedin

Karp

2020

J of Clinical Apheresis

View full text Add to dashboard Cite

A 58-year-old man developed cardiogenic shock 12 months after undergoing orthotopic heart transplant. On hospital day 0, a heart biopsy was performed and mixed antibody-and cellular-mediated rejection was diagnosed. Underdosing of his immunosuppressive medication was suspected, as the patient reported compliance with his medication regimen and had no other recent illnesses. After failing to improve with methylprednisolone, intravenous immunoglobulin, thymoglobulin, and mycophenolate mofetil, therapeutic plasma exchange (TPE) was requested as part of management of the antibody-mediated rejection. A series of five TPE was planned, exchanging one plasma volume using plasma as the replacement fluid (Spectra Optia Apheresis System, Terumo BCT, Lakewood, Colorado). 1 Donor plasma was chosen as the replacement fluid due to extracorporeal membrane oxygenation requirement and the possible need for emergent surgical intervention. Within minutes of initiating the first TPE, the patient's waste plasma was noted to have a reddish-brown discoloration, as typically seen in patients with intravascular hemolysis (Figure 1). A review of the patient's medical record revealed that hydroxocobalamin 5000 mg had been administered intravenously approximately 24 hours previously to treat vasoplegic syndrome (VS). VS is defined as "hypotension with evidence of endorgan hypoperfusion in the presence of normal or elevated cardiac output" and is typically treated with vasopressors. 2 Hydroxocobalamin, also known as vitamin B12, is a nitric oxide scavenger that has an emerging role as an adjunct therapy for VS not responsive to vasopressors. Hydroxocobalamin is known to cause red or purple discoloration of plasma and urine, which may result in interference with clinical laboratory assays that rely on colorimetric methodologies. 3-5 Intravascular hemolysis was excluded by a stable hemoglobin (9.0 g/ dL pre-TPE, 8.9 g/dL post-TPE). Although post-TPE total bilirubin was mildly elevated at 1.3 mg/dL (reference range: 0.1-0.9 mg/dL), indirect bilirubin was 0.5 mg/dL (reference range 0.1-0.6 mg/dL), and lactate dehydrogenase was mildly elevated but stable at 388 IU/L compared to 376 IU/L pre-TPE (reference range: 125-240 IU/L). Haptoglobin was not measured. Apheresis providers should be aware that hydroxocobalamin may cause discoloration of waste plasma that mimics intravascular hemolysis.

show abstract

Section: Figurementioning

confidence: 99%

Hydroxocobalamin mimicking intravascular hemolysis in therapeutic plasma exchange

Peedin

Karp

2020

J of Clinical Apheresis

View full text Add to dashboard Cite

show abstract

Drugs and Conditions That May Mimic Hemolysis

Jones

Sapatnekar

Bakdash

2022

American Journal of Clinical Pathology

View full text Add to dashboard Cite

Objectives Visual inspection of posttransfusion plasma for hemolysis is a key laboratory method in the investigation of possible acute hemolytic transfusion reactions (AHTRs). Many substances and physiologic conditions can mimic hemolysis in vitro. Isolated reports describe specific cases of interference, but a comprehensive listing is lacking. Methods Using an illustrative case, we summarize available literature on substances and conditions that may mimic hemolysis in vitro. We further describe other substances and conditions that may discolor plasma but are unlikely to be mistaken for hemolysis on visual inspection. Results At least 11 substances and conditions have been reported to discolor plasma, in colors ranging from orange to red to brown, including relatively common therapies (eg, eltrombopag, hydroxocobalamin, iron dextran). Other substances are unlikely to be encountered in everyday practice but may mimic hemolysis in particular patient populations. Additional substances may cause plasma discoloration, ranging from blue to green to white, and are associated with a wide variety of therapies and conditions. Conclusions An awareness of the possible preanalytic confounding factors that may mimic hemolysis can aid in the workup of a suspected AHTR. Review of the medical record, use of ancillary testing, and consideration for nonimmune causes of hemolysis can aid in ruling out AHTR.

show abstract

Hydroxocobalamin administration for treatment of vasoplegic syndrome associated with cardiopulmonary bypass causes red plasma

Cited by 2 publications

References 5 publications

Hydroxocobalamin mimicking intravascular hemolysis in therapeutic plasma exchange

Hydroxocobalamin mimicking intravascular hemolysis in therapeutic plasma exchange

Drugs and Conditions That May Mimic Hemolysis

Contact Info

Product

Resources

About